DanielLeeMD

Assistant Professor of Medicine, Division of Hematology and Medical Oncology, Columbia University Medical Center

Dr. Lee is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

New York Presbyterian Hospital (Columbia Campus)Fellowship, Hematology and Medical Oncology, 2014 - 2017
New York Presbyterian Hospital (Cornell Campus)Residency, Urology, 2010 - 2016
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 2011 - 2014
University of Virginia School of MedicineClass of 2011

PubMed

10 citations
Impact of the COVID-19 Pandemic on Treatment Patterns for Patients With Metastatic Solid Cancer in the United States.
Ravi B Parikh, Samuel U Takvorian, Daniel Vader, E Paul Wileyto, Amy S Clark
Journal of the National Cancer Institute. 2022-04-11
4 citations
Low-Dose Radiotherapy Versus Moderate-Dose Radiotherapy for the Treatment of Indolent Orbital Adnexal Lymphomas.
Jonathan Baron, Christopher M. Wright, Daniel Y. Lee, Maribel Carpenter, S.H. Manjunath
Frontiers in Oncology. 2021-01-01
10 citations
Definitive tumor directed therapy confers a survival advantage for metachronous oligometastatic HPV-associated oropharyngeal cancer following trans-oral robotic surgery.
Christopher M. Wright, Daniel Y. Lee, David Shimunov, Ruben Carmona, Andrew R. Barsky
Oral Oncology. 2021-10-01

Journal Articles

Improved CNS Exposure to Tocilizumab After Cerebrospinal Fluid Compared to Intravenous Administration in Rhesus Macaques
Brigitte C Widemann, Daniel W Lee, Anandani Nellan, Blood

Abstracts/Posters

Infectious Complications Associated with CAR T-Cell Therapy
Daniel W. Lee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Combination Thioguanine and Decitabine Is Highly Active in Patients with Advanced Myeloid Malignancies: A Single Institution Experience
Daniel J. Lee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results
Daniel J. Lee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019